A study published in the Journal of Clinical Medicine evaluated the improvement of bone mineral density in patients with type 1 Gaucher disease (GD1) treated with velaglucerase alfa.
GD1 is the most common form of Gaucher disease, characterized by a deficiency of glucocerebrosidase (GBA), an important enzyme that breaks down glucocerebroside. Symptoms of GD1 include enlarged spleen and liver, low blood cell counts, bleeding problems and bone disease. Gaucher disease is caused by changes in the GBA gene.
This phase 4 SHP-GCB-402 study evaluated the effect of velaglucerase alfa on lumbar spine (LS) bone density in patients with GD1. Velaglucerase alfa is an enzyme replacement therapy used for the long-term treatment of pediatric and adult patients with GD1. A total of 21 patients with documented bone pathology received 1 or more dose of velaglucerase alfa 60 U/kg, with 16 completing the study.
The primary endpoint, change from baseline to 24 months in an LS bone mineral density (BMD) Z-score, showed improvement from baseline to 24 months, although statistical significance was not reached. This was inconsistent with previous velaglucerase alfa studies.
A pooled analysis of 24-month data from previous velaglucerase alfa trials was conducted. In a cohort of 40 patients, a statistically significant mean increase in the LS BMD Z-score of 0.55 was observed, supporting the therapeutic potential of velaglucerase alfa in improving skeletal outcomes. Additionally, a significant reduction in the bone marrow burden (BMB) score was observed, indicating a positive effect on bone marrow infiltration.
All patients experienced 1 or more treatment-emergent adverse event, mostly of mild or moderate severity.
To learn more about Gaucher disease and other rare musculoskeletal conditions, visit https://checkrare.com/diseases/musculoskeletal-diseases/